Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats

dc.contributor.authorAksit, Dilek
dc.contributor.authorYalinkilinc, Hande Sultan
dc.contributor.authorSekkin, Selim
dc.contributor.authorBoyacioglu, Murat
dc.contributor.authorAyaz, Erol
dc.contributor.authorGokbulut, Cengiz
dc.contributor.buuauthorCirak, Veli Yilgor
dc.contributor.departmentUludağ Üniversitesi/Veteriner Fakültesi/Klinik Öncesi Bilimler Bölümü.tr_TR
dc.contributor.orcid0000-0003-0570-2514tr_TR
dc.contributor.researcheridFYC-2043-2022tr_TR
dc.contributor.scopusid6602404057tr_TR
dc.date.accessioned2023-10-06T05:19:07Z
dc.date.available2023-10-06T05:19:07Z
dc.date.issued2015-12-12
dc.description.abstractBackground: The aims of this study were to compare the pharmacokinetics of albendazole sulfoxide (ABZ-SO, ricobendazole) in goats and sheep at a dose of 5 mg/kg bodyweight (BW), after intravenous (IV) and subcutaneous (SC) administrations, and to investigate the effects of increased doses (10 and 15 mg/kg BW) on the plasma disposition of ABZ-SO in goats following SC administration. A total of 16 goats (Capra aegagrus hircus, eight males and eight females) and 8 sheep (Ovis aries, four males and four females) 12-16 months old and weighing 20-32 kg, were used. The study was designed according to two-phase crossover study protocol. In Phase-1, eight sheep were assigned as Group I and 16 goats were allocated into two groups (Group II and Group III). ABZ-SO was applied to Group I (sheep) and Group II (goats) animals subcutaneously, and to Group III (goats) animals intravenously, all at a dose rate of 5 mg/kg BW. In Phase-2, the sheep in the Group I received ABZ-SO intravenously in a dose of 5 mg/kg BW; the goats in Group II and Group III received ABZ-SO subcutaneously at a dose of 10 mg/kg and 15 mg/kg BW, respectively. Blood samples were collected from the jugular vein at different times between 1 and 120 h after drug administrations. The plasma concentrations of ABZ-SO and its metabolites were analysed by high performance liquid chromatography. Results: In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of 5 mg/kg BW. On the other side, dose-dependent plasma dispositions of ABZ-SO were observed following SC administration at increased doses (10 and 15 mg/kg) in goats. Conclusions: Consequently, ABZ-SO might be used at higher doses to provide higher plasma concentration and thus to achieve greater efficacy against the target parasites.en_US
dc.identifier.citationAksit, D. vd. (2015). "Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats". BMC Veterinary Research, 11(1)en_US
dc.identifier.issn1746-6148
dc.identifier.issue1tr_TR
dc.identifier.pubmed26012791tr_TR
dc.identifier.scopus2-s2.0-85019263294tr_TR
dc.identifier.urihttps://doi.org/10.1186/s12917-015-0442-5
dc.identifier.urihttps://bmcvetres.biomedcentral.com/articles/10.1186/s12917-015-0442-5
dc.identifier.urihttp://hdl.handle.net/11452/34230
dc.identifier.volume11tr_TR
dc.identifier.wos000355077700001
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherBMCen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalBMC Veterinary Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.relation.tubitak109 O 862tr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectVeterinary sciencestr_TR
dc.subjectBenzimidazolestr_TR
dc.subjectAlbendazoletr_TR
dc.subjectAlbendazole sulfoxidetr_TR
dc.subjectPharmacokineticstr_TR
dc.subjectEnantiomerstr_TR
dc.subjectSheeptr_TR
dc.subjectGoattr_TR
dc.subjectDairy goatstr_TR
dc.subjectEnantiomerstr_TR
dc.subjectRicobendazoletr_TR
dc.subjectMetabolitestr_TR
dc.subjectFenbendazoletr_TR
dc.subjectOxfendazoletr_TR
dc.subjectNetobimintr_TR
dc.subjectBehaviortr_TR
dc.subjectPharmacologytr_TR
dc.subjectFormulationtr_TR
dc.subjectBenzimidazolestr_TR
dc.subjectSheeptr_TR
dc.subjectAnimaliatr_TR
dc.subjectCapra hircustr_TR
dc.subjectOvis ariestr_TR
dc.subject.emtreeAlbendazoletr_TR
dc.subject.emtreeAlbendazole sulfoxidetr_TR
dc.subject.emtreeAnthelmintic agenttr_TR
dc.subject.emtreeAnalogs and derivativestr_TR
dc.subject.emtreeAnimaltr_TR
dc.subject.emtreeArea under the curvetr_TR
dc.subject.emtreeBloodtr_TR
dc.subject.emtreeDose responsetr_TR
dc.subject.emtreeFemaletr_TR
dc.subject.emtreeGoattr_TR
dc.subject.emtreeHalf life timetr_TR
dc.subject.emtreeIntravenous drug administrationtr_TR
dc.subject.emtreeMaletr_TR
dc.subject.emtreeMetabolismtr_TR
dc.subject.emtreeSheeptr_TR
dc.subject.emtreeSpecies differencetr_TR
dc.subject.emtreeSubcutaneous drug administrationtr_TR
dc.subject.meshAdministration, Intravenoustr_TR
dc.subject.meshAlbendazoletr_TR
dc.subject.meshAnimalstr_TR
dc.subject.meshAnthelminticsen_US
dc.subject.meshArea under curveen_US
dc.subject.meshDose-response relationship, Drugen_US
dc.subject.meshFemaleen_US
dc.subject.meshGoatsen_US
dc.subject.meshHalf-lifeen_US
dc.subject.meshInjections, Subcutaneousen_US
dc.subject.meshMaleen_US
dc.subject.meshSheepen_US
dc.subject.meshSpecies specificityen_US
dc.subject.scopusAlbendazole; Benzimidazole; Anthelmintic agenten_US
dc.subject.wosVeterinary sciencesen_US
dc.titleComparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goatsen_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: